By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs,

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.

Danish drugmaker Novo Nordisk (NVO) is investing $1.20 billion U.S. in a new facility that will produce medications to treat rare diseases. <

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the rare disease area, such as haemophilia.

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help meet growing demand for its blockbuster drugs.

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. The company said in a statement the site will include a warehouse as well as a factory.

Danish pharma giant Novo Nordisk (NVO) will make a significant investment of approximately $1.2 billion to construct a new production facility in Odense, Denmark. The new facility will focus on the manufacturing of medications used for rare diseases,

Danish healthcare firm Novo Nordisk announced plans on Monday for new investment in a production facility in one of the country's largest cities, Odense. Novo Nordisk said it plans to invest 8.5 billion Danish kroner ($1.